Immunotherapy of early, intermediate and late primary Meth A tumors demonstrating antigen specificity of gp96, timing of treatment and dosage - Summary of the data in Figure 1. (A) Tumor-bearing mice were treated with tumor-derived gp96, liver-derived gp96 or buffer alone. Tumor diameters were monitored. (B) Tumor-bearing mice received gp96-adjuvant therapy starting on day 5 (early), day 7 (intermediate) or day 9 (late). Tumor diameters were monitored. (C) Tumor-bearing mice were treated with varying doses of Meth A-derived gp96. Amounts indicated in the legend represent the dose given per injection 4 times on alternate days. Tumor diameters were monitored. Each line is an average of the data from 5 animals.